HC Wainwright Brokers Decrease Earnings Estimates for LRMR

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.91) per share for the year, down from their previous estimate of ($1.77). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

Several other equities research analysts have also issued reports on LRMR. Robert W. Baird dropped their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday. Truist Financial started coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Stock Performance

LRMR opened at $2.25 on Thursday. The company has a market cap of $143.57 million, a PE ratio of -1.96 and a beta of 0.99. Larimar Therapeutics has a 1 year low of $2.19 and a 1 year high of $11.20. The firm has a 50 day moving average price of $3.11 and a 200 day moving average price of $5.18.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its holdings in Larimar Therapeutics by 321.2% in the third quarter. Barclays PLC now owns 60,032 shares of the company’s stock valued at $393,000 after buying an additional 45,781 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Larimar Therapeutics by 27.2% in the 3rd quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after buying an additional 1,189,467 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Larimar Therapeutics by 35.1% in the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock worth $75,000 after buying an additional 5,042 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Larimar Therapeutics in the 3rd quarter valued at about $100,000. Finally, Franklin Resources Inc. grew its position in shares of Larimar Therapeutics by 21.9% during the 3rd quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock valued at $143,000 after buying an additional 3,549 shares during the last quarter. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.